Where next for the Dow after breaking above 30,000?
Fiona Cincotta November 25, 2020 11:19 AM
The Dow Jones climbed over 400 points in the previous session, crossing 30,000 for the first time ever amid upbeat vaccine news, optimism surrounding the economic recovery & US political clarity.
The Dow Jones climbed over 400 points in the previous session, crossing 30,000 for the first time ever amid upbeat vaccine news, optimism surrounding a strong economic recovery in the coming year and improving political clarity after Trump’s administration approved the start of the transition presidential period.
News that ex-Federal Reserve Chair Janet Yellen will be Treasury Secretary also gave the markets a boost given that she is seen as a market friendly candidate and one who will work closely with Jerome Powell. Markets are interpreting her appointment as a sign that Joe Biden could focus more on rebuilding the economy than rather than pursuing aggressive regulatory policy.
The rally from 20,000 (crossed January 2017) – 30,000 was helped by a big lift from tech with Apple, Microsoft and Salesforce surging over 230% across the same period. However, the latest runup the surge in the Dow is thanks in part to a catch up trade in value stocks. Across the pandemic, big tech was massively in favour with investors basically rising the wave of 5 mega tech stocks. Now the doors have opened to a much broader selection of stocks. Value stocks have been hugely in favour this month on vaccine developments and hopes surrounding the economic recovery.
When big milestones are reached this can provoke Fear of Missing Out (FOMO) making a deep selloff after the milestone less likely. That said given the rapid run up from the lows could mean it needs to consolidate. As a result, reaching 40,000 could take longer than the 20,000 – 30,000 run up. There’s also a good chance that the market will want to see some more stimulus before pushing too much higher.
Sectors to watch
Tech is expected to remain a favourite but could well be joined by other sectors and industries. More recently investors have been backing cyclical stocks such as industrials, materials and financials. These are sectors that will do well when the economy reopens and rebounds next year
Health related stocks such as Johnson & Johnson, United Health could also have plenty of upside. Healthcare stocks have underperformed for a good part of the year on fears that a progressive Democrat in the White House would change healthcare legislation. The group has advanced since Joe Biden won, but there could well be more steam left in this rally , especially if a Blue wave looks less likely.
Disclaimer: GAIN Capital UK Limited (trading as "Forex.com") is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, Forex.com does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by Forex.com or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although Forex.com is not specifically prevented from dealing before providing this material, Forex.com does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.
For further details see our full non-independent research disclaimer and quarterly summary.